BeyondSpring (BYSI)
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology...
- Open
- 0.7600
- High
- 1.3500
- Low
- 0.7600
- Prev. Close
- 0.7420
- Volume
- 38.97M
- Turnover
- 41.60M
- Avg Price
- 1.0674
- Bid/Ask Ratio
- --
- Amplitude
- 79.51%
- 52wk High
- 2.4400
- Volume Ratio
- 1,287.78
- Turnover Ratio
- 121.98%
BeyondSpring Analyst Rating
View moreForecast & Rating
Nov 7, 2023Price forecast
$1.2525.46%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 9 hours ago
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
- benzinga_article · 11 hours ago
12 Health Care Stocks Moving In Thursday's Intraday Session
- PUBT · Jul 9 at 01:18 PM
BeyondSpring posts corporate presentation spotlighting plinabulin immune-modulating cancer therapy pipeline
- PUBT · Jul 6 at 12:09 PM
BeyondSpring files Form 3 for CFO Na Li showing no beneficial ownership
- PUBT · Jun 29 at 03:31 PM
BeyondSpring amends filing to disclose CEO Min Qiu pay package, including USD 100,000 salary
- TradingView · Jun 4 at 06:33 AM
BeyondSpring appoints Min Qiu as CEO and Na Li as CFO; Lan Huang to remain as Chair
